Market revenue in 2023 | USD 209.8 million |
Market revenue in 2030 | USD 417.9 million |
Growth rate | 10.3% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Non-cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 85.94% in 2023. Horizon Databook has segmented the India hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Genetic testing solutions are gaining popularity in diagnosis and treatment of inherited medical conditions in India. An increasing number of genetic tests are adopted to monitor a patient’s predisposition to diseases and making decisions for treatment for certain cancers.
The lost cost of a genetic test in India, compared to other countries, supports the expansion of genetic testing in this country. For example, a genetic test for thalassemia, an inherited blood disorder, costs around USD 42.06 (Rs 3,000).
In addition, processing of multiple samples at the same time acts as a cost-effective choice, such as 152-gene Strand Advantage test provided by Strand Life Sciences. These factors are expected to propel genetic testing in India. Hereditary testing companies operating in India include local and international companies.
Horizon Databook provides a detailed overview of country-level data and insights on the India hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into India hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account